{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T14:26:54Z","timestamp":1649082414957},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[1989,5,1]],"date-time":"1989-05-01T00:00:00Z","timestamp":609984000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1989,5]]},"DOI":"10.1007\/bf00292406","type":"journal-article","created":{"date-parts":[[2004,11,11]],"date-time":"2004-11-11T07:28:41Z","timestamp":1100158121000},"page":"291-295","source":"Crossref","is-referenced-by-count":2,"title":["The effect of cimetidine, phenobarbitone and buthionine sulphoximine on the disposition of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamino) phenylamino]-4-acridinecarboxamide (CI-921) in the rabbit"],"prefix":"10.1007","volume":"23","author":[{"given":"J. W.","family":"Paxton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. C.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. R.","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","first-page":"967","volume":"67","author":"ZA Arlin","year":"1983","unstructured":"Arlin ZA (1983) Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia. Cancer Treat Rep 67: 967?970","journal-title":"Cancer Treat Rep"},{"key":"CR2","first-page":"3245","volume":"44","author":"BC Baguley","year":"1984","unstructured":"Baguley BC, Denny WA, Atwell GJ, Finlay GJ, Rewcastle GW, Twigden SJ, Wilson W (1984) Synthesis, antitumour activity and DNA binding properties of a new derivative of amsacrine; N-5-dimethyl-9[(2-methoxy-4-methylsulfonylamino)phenylamino]-4-acridinecarboxamide. Cancer Res 44: 3245?3251","journal-title":"Cancer Res"},{"key":"CR3","volume-title":"Amsacrine: current perspectives and clinical results with a new anticancer agent","year":"1983","unstructured":"Bodey GP, Jacquillat C (eds) (1983) In: Amsacrine: current perspectives and clinical results with a new anticancer agent. Communications Media for Education Inc., New Jersey"},{"key":"CR4","first-page":"1651","volume":"66","author":"RM Bukowski","year":"1982","unstructured":"Bukowski RM, Legha SS, Saiki J, Eyre HJ, O'Bryan RO (1982) Phase II trial of m-AMSA in hepatocellular carcinoma; a Southwest Oncology Group Study. Cancer Treat Rep 66: 1651?1652","journal-title":"Cancer Treat Rep"},{"key":"CR5","first-page":"1992","volume":"66","author":"A Drelichman","year":"1982","unstructured":"Drelichman A, Decker DA, Al-Sarraf M, Dhabuwala CO (1982) m-AMSA in disseminated prostatic carcinoma: a phase II study. Cancer Treat Rep 66: 1992?1994","journal-title":"Cancer Treat Rep"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1016\/0006-2952(84)90598-7","volume":"33","author":"R Drew","year":"1984","unstructured":"Drew R, Miners JO (1984) The effects of buthionine sulphoximine (BSO) on glutathione depletion and xenobiotic biotransformation. Biochem Pharmacol 33: 2989?2994","journal-title":"Biochem Pharmacol"},{"key":"CR7","first-page":"3422","volume":"43","author":"SW Hall","year":"1983","unstructured":"Hall SW, Freidman J, Legha SS, Benjamin RS, Gutterman JV, Loo TL (1983) Human pharmacokinetics of a new acridine derivative, 4?-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992). Cancer Res 43: 3422?3426","journal-title":"Cancer Res"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0378-4347(00)84539-9","volume":"343","author":"JL Jurlina","year":"1985","unstructured":"Jurlina JL, Paxton JW (1985) A high-performance liquid chromatographic assay for plasma concentrations of N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenylamino]-4-acridinecarboxamide (CI-921, NSC 343499). J Chromatogr 343: 431?435","journal-title":"J Chromatogr"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF00552719","volume":"14","author":"JL Jurlina","year":"1985","unstructured":"Jurlina JL, Varcoe AR, Paxton JW (1985) Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia. Cancer Chemother Pharmacol 14: 21?25","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1182\/blood.V60.2.484.484","volume":"60","author":"SS Legha","year":"1982","unstructured":"Legha SS, Keating MJ, McCredie KB, Bodey GP, Freireich EJ (1982) Evaluation of AMSA in previously treated patients with acute leukemia. Results of therapy in 109 adults. Blood 60: 484?490","journal-title":"Blood"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev.pa.18.040178.000501","volume":"18","author":"WG Levine","year":"1978","unstructured":"Levine WG (1978) Biliary excretion of drugs and other xenobiotics. Ann Rev Pharmacol Toxicol 18: 81?90","journal-title":"Ann Rev Pharmacol Toxicol"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1126\/science.6836290","volume":"220","author":"A Meister","year":"1983","unstructured":"Meister A (1983) Selective modification of glutathione metabolism. Science 220: 472?477","journal-title":"Science"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF00293987","volume":"16","author":"JW Paxton","year":"1986","unstructured":"Paxton JW, Jurlina JL (1986) Comparison of the pharmacokinetics and protein binding of the anticancer drug amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenylamino]-4-acridinecarboxamide in rabbits. Cancer Chemother Pharmacol 16: 253?256","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/BF00273387","volume":"18","author":"JW Paxton","year":"1986","unstructured":"Paxton JW, Foote SE, Singh RM (1986) The effect of buthionine sulphoximine, cimetidine and phenobarbitone on the disposition of amsacrine in the rabbit. Cancer Chemother Pharmacol 18: 208?212","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF00252952","volume":"20","author":"JW Paxton","year":"1987","unstructured":"Paxton JW, Evans PC, Singh RM (1987) Dose-dependent pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino]-4-acridinecarboxamide (CI-921) in rabbits. Cancer Chemother Pharmacol 20: 13?16","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/BF01060128","volume":"12","author":"A Rakhit","year":"1984","unstructured":"Rakhit A, Holford NHG, Effeney DJ, Riegelman S (1984) Induction of quinidine metabolism and plasma protein binding of phenobarbital in dogs. J Pharmacokinet Biopharma 12: 495?515","journal-title":"J Pharmacokinet Biopharma"},{"key":"CR17","first-page":"467","volume":"8","author":"DD Shoemaker","year":"1980","unstructured":"Shoemaker DD, Gormley PE, Cysyk RL (1980) Biliary excretion of 4?-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in rats: effects of pretreatment with diethylmaleate, phenobarbital and metapyrone. Drug Metab Dispos 8: 467?468","journal-title":"Drug Metab Dispos"},{"key":"CR18","first-page":"35","volume":"8","author":"DD Shoemaker","year":"1982","unstructured":"Shoemaker DD, Cysyk RL, Padmanabhan S, Bhat MB, Malspeis L (1982) Identification of the principal biliary metabolite of 4?-(9-acridinylamino)methane-sulphon-m-anisidide in rats. Drug Metab Dispos 8: 35?39","journal-title":"Drug Metab Dispos"},{"key":"CR19","first-page":"1939","volume":"44","author":"DD Shoemaker","year":"1984","unstructured":"Shoemaker DD, Cysyk RL, Gormley PE, De Sauza JJV, Malspeis L (1984) Metabolism of 4?-(9-acridinylamino)methanesulphon-m-anisidide by rat liver microsomes. Cancer Res 44: 1939?1945","journal-title":"Cancer Res"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/0003-2697(69)90064-5","volume":"27","author":"F Tietze","year":"1969","unstructured":"Tietze F (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidised glutathione. Anal Biochem 27: 502?522","journal-title":"Anal Biochem"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00292406.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00292406\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00292406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T00:24:13Z","timestamp":1585959853000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00292406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1989,5]]}},"alternative-id":["BF00292406"],"URL":"https:\/\/doi.org\/10.1007\/bf00292406","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989,5]]}}}